Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
9.41
+0.32 (3.52%)
Mar 20, 2026, 11:03 AM EDT - Market open

Rallybio Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
0.860.64---
Revenue Growth (YoY)
34.91%----
Gross Profit
0.860.64---
Selling, General & Admin
14.3319.6325.3927.218.74
Research & Development
19.641.5153.5440.6926.91
Total Operating Expenses
33.9261.1378.9367.8845.65
Operating Income
-33.06-60.5-78.93-67.88-45.65
Interest Income
2.194.226.151.960.05
Interest Expense
-----0.01
Other Non-Operating Income (Expense)
21.9-1.5-1.78-0.73-1.41
Total Non-Operating Income (Expense)
24.092.724.371.23-1.37
Pretax Income
-8.98-57.78-74.56-66.65-47.01
Net Income
-8.98-57.78-74.56-66.65-47.01
Net Income to Common
-8.98-57.78-74.56-66.65-47.01
Shares Outstanding (Basic)
65543
Shares Outstanding (Diluted)
65543
Shares Change (YoY)
3.42%7.66%27.11%24.70%46.76%
EPS (Basic)
-1.59-10.61-14.72-16.72-14.72
EPS (Diluted)
-1.59-10.61-14.72-16.72-14.72
Free Cash Flow
-29.81-49.28-60.28-57.34-45.87
Free Cash Flow Per Share
-5.30-9.05-11.92-14.41-14.38
Gross Margin
100.00%100.00%---
Operating Margin
-3853.61%-9511.95%---
Profit Margin
-1046.39%-9084.12%---
FCF Margin
-3474.71%-7748.74%---
EBITDA
-32.97-60.37-78.78-67.72-45.54
EBITDA Margin
-3842.89%-9491.35%---
EBIT
-33.06-60.5-78.93-67.88-45.65
EBIT Margin
-3853.61%-9511.95%---
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q